Neogenomics (NEO) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$164.1 million.
- Neogenomics' Enterprise Value rose 5768.14% to -$164.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.1 million, marking a year-over-year increase of 5768.14%. This contributed to the annual value of -$386.8 million for FY2024, which is 683.02% up from last year.
- Per Neogenomics' latest filing, its Enterprise Value stood at -$164.1 million for Q3 2025, which was up 5768.14% from -$163.7 million recorded in Q2 2025.
- In the past 5 years, Neogenomics' Enterprise Value registered a high of -$163.7 million during Q2 2025, and its lowest value of -$802.7 million during Q1 2021.
- Over the past 5 years, Neogenomics' median Enterprise Value value was -$415.2 million (recorded in 2023), while the average stood at -$428.4 million.
- As far as peak fluctuations go, Neogenomics' Enterprise Value plummeted by 83060.03% in 2021, and later surged by 5779.74% in 2025.
- Over the past 5 years, Neogenomics' Enterprise Value (Quarter) stood at -$515.4 million in 2021, then increased by 15.02% to -$438.0 million in 2022, then increased by 5.2% to -$415.2 million in 2023, then grew by 6.83% to -$386.8 million in 2024, then skyrocketed by 57.58% to -$164.1 million in 2025.
- Its last three reported values are -$164.1 million in Q3 2025, -$163.7 million for Q2 2025, and -$358.1 million during Q1 2025.